ARVO

Articles

In a presentation at ARVO, Friederike Kortuem, MD, MSc, explains that treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood. 


Foveal morphologic changes in LCA sparked by gene therapy

Videos

Michael A. Singer, MD, speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).

Analysis of 24-month data from the PALADIN study

Theodore Leng, MD, discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," during the virtual 2021 ARVO meeting. 

A look at real-world trial data replication outcomes from IRIS Registry data 

Michael Mbagwu, MD, speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.  

Linking patient imaging data to AAO IRIS Registry

Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.

Analyzing clinical results of dexamethasone implant effect on macular thickness

Clinicians' knowledge of the epidemiology, natural history, causal mechanisms, and treatments for diabetic retinopathy (DR) has evolved dramatically over recent decades.

Diabetes and DR: Progress in a global epidemic 

EYS809, a non-viral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor to the eye, may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet age-related macular degeneration. 

Wet AMD treatment burden eased by nonviral gene therapy 

Logan Vander Woude, DO, MPH, examines research on improved resolution of symptomatic vitreomacular traction as an attempt to further refine the potential factors predictive of better outcomes.

Novel factors predict ocriplasmin efficacy in symptomatic vitreomacular traction

Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.

Targeting neurodegenerative diseases with risuteganib as treatment therapy

Robyn Guymer, PhD, MBBS, highlights the latest trial results for faricimab, the first bispecific antibody designed for intraocular use in treating patients with neovascular age-related macular degeneration.